Human Cell

, Volume 32, Issue 2, pp 214–222 | Cite as

Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma

  • Fusako Kito
  • Rieko Oyama
  • Marimu Sakumoto
  • Kumiko Shiozawa
  • Zhiwei Qiao
  • Shunichi Toki
  • Akihiko Yoshida
  • Akira Kawai
  • Tadashi KondoEmail author
Research Article


Myxofibrosarcoma (MFS) is an aggressive sarcoma that requires novel therapeutic approaches to improve its clinical outcome. Cell lines are a valuable tool for pre-clinical research; however, there is a lack of patient-derived cell lines of MFS available from public cell banks. This study aimed to develop a patient-derived cell line of MFS. A cell line designated NCC-MFS1-C1 was established from the primary tumor tissue of an 82-year-old male patient with MFS. The short tandem repeat pattern of NCC-MFS1-C1 cells was identical to that of the original tumor, but distinct from that of any other cell lines in public cell banks. NCC-MFS1-C1 cells were maintained as a monolayer culture for over 20 passages in 19 months; the cells exhibited spindle-like morphology, continuous growth, and ability for spheroid formation and invasion. Genomic assay showed that NCC-MFS1-C1 cells had gain and loss of genetic loci. Proteomic profiling revealed that the original tumor and the derived NCC-MFS1-C1 cells had similar, but distinct protein expression patterns. Screening of anti-cancer drugs in NCC-MFS1-C1 cells identified five candidate drugs for MFS. In conclusion, we established a novel MFS cell line, NCC-MFS1-C1, which could be used to study tumor development and effects of anti-cancer drugs.


Myxofibrosarcoma Cell line Proteomics Drug screening 



We thank Drs. M. Endo, Y. Minami, K. Shimizu, T. Mori, T. Uehara, M. Sugawara, Y. Araki, and Ms. R. Nakano of the Division of Musculoskeletal Oncology, National Cancer Center Hospital for sampling tumor tissue specimens from surgically resected materials. Fundamental Innovative Oncology Core at the National Cancer Center provided support for the SNP array experiment. We would like to thank Editage ( for English language editing and constructive comments on the manuscript.


This study was funded by the National Cancer Center Research and Development Fund (26-A-9 and 29-A-2).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Supplementary material

13577_2018_233_MOESM1_ESM.xlsx (23 kb)
Supplementary material 1 (XLSX 23 KB)
13577_2018_233_MOESM2_ESM.xlsx (3.9 mb)
Supplementary material 2 (XLSX 3966 KB)
13577_2018_233_MOESM3_ESM.xlsx (2.6 mb)
Supplementary material 3 (XLSX 2711 KB)
13577_2018_233_MOESM4_ESM.xlsx (14 kb)
Supplementary material 4 (XLSX 14 KB)


  1. 1.
    Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. WHO classification of tumours of soft tissue and bone. Fourth edn. Geneva: WHO Press; 2013.Google Scholar
  2. 2.
    Haglund KE, Raut CP, Nascimento AF, Wang Q, George S, Baldini EH. Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma. Int J Radiat Oncol Biol Phys. 2012;82:361–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Sanfilippo R, Miceli R, Grosso F, et al. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2011;18:720–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Mentzel T, Calonje E, Wadden C, et al. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol. 1996;20:391–405.CrossRefPubMedGoogle Scholar
  5. 5.
    Merck C, Angervall L, Kindblom LG, Oden A. Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastic-histiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis. Acta pathologica, microbiologica, et immunologica Scandinavica Supplement. 1983; 282:1–40.Google Scholar
  6. 6.
    Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer. 1977;39:1672–85.CrossRefPubMedGoogle Scholar
  7. 7.
    Willems SM, Debiec-Rychter M, Szuhai K, Hogendoorn PC, Sciot R. Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol. 2006;19:407–16.CrossRefPubMedGoogle Scholar
  8. 8.
    Lin CN, Chou SC, Li CF, et al. Prognostic factors of myxofibrosarcomas: implications of margin status, tumor necrosis, and mitotic rate on survival. J Surg Oncol. 2006;93:294–303.CrossRefPubMedGoogle Scholar
  9. 9.
    Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Iorio F, Knijnenburg TA, Vis DJ, et al. A landscape of pharmacogenomic interactions in cancer. Cell. 2016;166:740–54.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kawashima H, Ogose A, Gu W, et al. Establishment and characterization of a novel myxofibrosarcoma cell line. Cancer Genet Cytogenet. 2005;161:28–35.CrossRefPubMedGoogle Scholar
  12. 12.
    Huang HY, Wu WR, Wang YH, et al. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clin Cancer Res. 2013;19:2861–72.CrossRefPubMedGoogle Scholar
  13. 13.
    Lohberger B, Stuendl N, Wolf E, Liegl-Atzwanger B, Leithner A, Rinner B. The novel myxofibrosarcoma cell line MUG-Myx1 expresses a tumourigenic stem-like cell population with high aldehyde dehydrogenase 1 activity. BMC Cancer. 2013;13:563.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Salawu A, Fernando M, Hughes D, et al. Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines. Br J Cancer. 2016;115:1058–68.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Lohberger B, Stuendl N, Leithner A, et al. Establishment of a novel cellular model for myxofibrosarcoma heterogeneity. Scientific reports. 2017;7:44700.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Ariizumi T, Ogose A, Kawashima H, Hotta T, Umezu H, Endo N. Multinucleation followed by an acytokinetic cell division in myxofibrosarcoma with giant cell proliferation. J Exp Clin Cancer Res. 2009;28:44.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Willems SM, Mohseny AB, Balog C, et al. Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix. J Cell Mol Med. 2009;13:1291–301.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Willems SM, van Remoortere A, van Zeijl R, Deelder AM, McDonnell LA, Hogendoorn PC. Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumour type and grade, and reveals biochemical intratumour heterogeneity. J Pathol. 2010;222:400–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Jones EA, van Remoortere A, van Zeijl RJ, et al. Multiple statistical analysis techniques corroborate intratumor heterogeneity in imaging mass spectrometry datasets of myxofibrosarcoma. PLoS One. 2011;6:e24913.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Workgroup ATCCSDO. Cell line misidentification: the beginning of the end. Nat Rev Cancer. 2010;10:441–8.CrossRefGoogle Scholar
  21. 21.
    Capes-Davis A, Reid YA, Kline MC, et al. Match criteria for human cell line authentication: where do we draw the line? Int J Cancer. 2013;132:2510–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Capes-Davis A, Dirks W, MacLeod R, Uphoff C. Quality matters: cell lines and their use in research. GIT Lab J Eur. 2014;17:12–3.Google Scholar
  23. 23.
    Kondo T, Hirohashi S. Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nat Protoc. 2007;1:2940–56.CrossRefGoogle Scholar
  24. 24.
    Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6:359–62.CrossRefPubMedGoogle Scholar
  25. 25.
    Baehrecke EH, Dang N, Babaria K, Shneiderman B. Visualization and analysis of microarray and gene ontology data with treemaps. BMC Bioinformatics. 2004;5:84.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4:2126.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Arai K, Sakamoto R, Kubota D, Kondo T. Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system. Proteomics. 2013;13:2351–60.CrossRefPubMedGoogle Scholar
  28. 28.
    Ben-David U, Ha G, Tseng YY, et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017.Google Scholar

Copyright information

© Japan Human Cell Society and Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  • Fusako Kito
    • 1
  • Rieko Oyama
    • 1
  • Marimu Sakumoto
    • 1
  • Kumiko Shiozawa
    • 2
  • Zhiwei Qiao
    • 2
  • Shunichi Toki
    • 3
  • Akihiko Yoshida
    • 4
  • Akira Kawai
    • 3
  • Tadashi Kondo
    • 1
    • 2
    Email author
  1. 1.Department of Innovative Seeds EvaluationNational Cancer Center Research InstituteTokyoJapan
  2. 2.Division of Rare Cancer ResearchNational Cancer Center Research InstituteTokyoJapan
  3. 3.Division of Musculoskeletal OncologyNational Cancer Center HospitalTokyoJapan
  4. 4.Pathology and Clinical Laboratory DivisionNational Cancer Center HospitalTokyoJapan

Personalised recommendations